Skip to main content

Articles By Hani El-Gabalawy, MD, FRCPC

question mark

Why aren’t we preventing RA yet?

Ever since the seminal studies demonstrating a prolonged preclinical period for seropositive RA, which have been replicated in multiple cohorts around the world using both retrospective and prospective study designs, the rheumatology community has been tantalized by the prospect of preventing the onset of inflammatory joint disease in seropositive individuals exhibiting no clinically detectable synovitis. So why can’t we prevent RA yet?

Read Article
×